Forecast for 2025 For the current fiscal year, Dräger expects an increase in net sales of 1.0 to 5.0 percent (net of currency effects) and an EBIT margin of 3.5 to 6.5 percent. The expected EBIT ...

PHYRAGO™ Represents the First and Only Improved Version of SPRYCEL® That Can Be Safely Co-administered With Gastric Acid-Reducing Agents TAIPEI, TAIWAN / ACCESSWIRE / January 15, 2025 / Handa ...

Cellev8's Brand Expands Beyond Consumers  WELLINGTON, FLORIDA / ACCESSWIRE / January 15, 2025 / Cellev8 Nutrition Inc., a leader in natural health supplements, is proud to announce an exclusive ...

Comprehensive Gratis Report Featuring Profiles and Client Engagement Ratings for 260 HIT Consulting and Advisory Firms TAMPA, FLORIDA / ACCESSWIRE / January 15, 2025 / Black Book Research announces ...

NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced oral drug delivery systems, today announced the ...

Also giving an in-session talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," showcasing Aptevo's drug engineering and rational drug design ...

Innovative Research Confirms Accuracy and Reliability of Online ADHD Diagnostic Evaluation GRAND RAPIDS, MICHIGAN / ACCESSWIRE / January 15, 2025 / Mentavi Health, a leader in evidence-based mental ...

FORT LAUDERDALE, FL / ACCESSWIRE / January 15, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of ...

BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new ...

Touchlight, an innovation-driven Contract Development and Manufacturing Organisation (CDMO), today announced that its facility in Hampton UK has received GMP certification. As a result, Touchlight ...

Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), has announced the development and upcoming launch of the new version of its proprietary V-OVS® syringe closure ...

Oxford Drug Design, the Oxford-based AI drug discovery company, has today announced additional in vivo validation for its first-in-class approach against cancer as the Company continues to apply its ...